Oxford's coronavirus vaccine shows promise in animal trials

Some of the monkeys given a single-shot of the vaccine developed antibodies against COVID-19, the disease caused by the new coronavirus, within 14 days, and all of them had done so within 28 days.

"It was a big hurdle for the Oxford vaccine, which they have overcome very well", he said. This vaccine prevented the virus from forming and growing its own copies in the body, but it was also found that the corona was still active in the nose.

In the latest update on its novel coronavirus vaccine efforts, British American Tobacco said on Friday it is "pleased to report the potential vaccine has been shown to produce a positive immune response" in pre-clinical testing and "is now poised to progress to the next stage which will be Phase 1 human clinical trials pending [US] FDA authorisation". They, however, warned that the vaccine can not be considered as COVID-19 cure yet until it is as effective in humans. The expert view is that a novel coronavirus vaccine is still around two years away. However, it is still not 100% certain that the results apply to humans.

Professor Evans says, "One of the good things, in this case, is that vaccines that don't work, instead of giving protection, often make the disease worse".

Researchers Scramble to Eradicate 'Murder Hornet' Species in US
They also have poisonous venom, with stingers that can penetrate a beekeeping suit. The comedian Patton Oswalt shared the story and wrote " murder hornets ".

"It was chosen as the most suitable vaccine technology for a SARS-CoV-2 (COVID-19) vaccine as it can generate a strong immune response from one dose and it is not a replicating virus, so it cannot cause an ongoing infection in the vaccinated individual", it added. The letter also asks all governments and global partners to unite and ensure when the vaccine is developed it is produced rapidly at a large scale and made available to all people in all countries.

Other vaccines in human trials include those by Moderna Inc, Pfizer Inc and BioNTech SE and China's CanSino Biologics Inc. The project has at least seven manufacturing sites around the world. A million doses of the shot are already being manufactured and will be available by September, even before trials fully prove whether it works. "So, large scale is feasible - we believe".

Fourteen days later, some of them developed protective antibodies against Covid-19.

  • Ismael Montgomery